Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.
about
Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studiesMR Imaging Biomarkers in Oncology Clinical TrialsSuggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib.Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer.Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort studyTherapeutic cancer vaccines: are we there yet?Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung CancerChange in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer.A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index.Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factorsEvaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancerComparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancerEnd points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis.Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.Volumetric evaluation of hepatic tumors: multi-vendor, multi-reader liver phantom study.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
P2860
Q26778463-5037F88A-FBEF-4FD3-AE7C-F85F81748A20Q30364608-DDA4ACD0-093E-4706-BCFA-2CE6D0CBC81CQ30437854-ADEA51C2-E4A6-4630-96C3-81A9F521F6E3Q33334597-1BE5B1C0-2B05-4332-9966-580EA892535FQ33882096-FF6D8F78-FFE2-42A6-AA54-E6C0F2A17479Q34023973-E7CE59F0-DD8F-4629-8073-68589804DB89Q34299723-00CE818D-B569-4326-BD2E-C92E08FB7B2FQ34734470-B91290E1-5A61-45AC-8E72-DEDD5C51CD9CQ34786691-4BCC332D-DC72-4F1E-8168-545117A83974Q35190735-8678C045-044B-4BEB-A988-093F8CF66AB1Q35648196-8B320BA0-2063-4C54-81BB-30C63854F569Q36145455-A7ED767E-3AA6-4F55-8F36-6701B98A87D1Q36216138-ABD03F41-DEE7-47F6-9D2A-BB62A27A17E8Q36614935-44B10B98-E7D8-4CB4-AE8E-CB545D159397Q36622856-0D97F994-4735-491F-9752-3F4648002DC7Q36648454-33599FB6-D929-4F7E-A7C2-7C4A843D1F1FQ36695064-D8957B2F-EA54-41FE-BBE5-151CC4F00AF6Q37952239-C9657D8B-81AB-40C5-83C3-6A23C7437959Q38803727-FED0C34E-586A-42B9-BB1C-020F8F267879Q39217214-C9B4D882-736C-4ECF-B766-3490664B08F3Q47287018-CB232F87-9B5D-4B1D-BA01-91E732B79CEBQ47417911-DE0C8C9E-42F7-4279-AC7F-A764CE188522Q48212247-82CE96EF-2225-4ED8-9EBC-912B9505CE4EQ52723563-E467A321-BE0A-4848-999E-10C8F68C8535Q53080830-5F0C8C15-62E9-440A-813B-D8CC4BC87F67Q53717818-BC5527C1-B45C-4F09-B8CC-885CE1E2EF26
P2860
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Response to chemotherapy has p ...... ean Lung Cancer Working Party.
@en
type
label
Response to chemotherapy has p ...... ean Lung Cancer Working Party.
@en
prefLabel
Response to chemotherapy has p ...... ean Lung Cancer Working Party.
@en
P2093
P1476
Response to chemotherapy has p ...... ean Lung Cancer Working Party.
@en
P2093
Klastersky J
Paesmans M
Sculier JP
Sergysels R
Thiriaux J
P304
P356
10.1016/S0959-8049(97)00325-0
P577
1997-12-01T00:00:00Z